Bavarian Nordic — Februar 2023
-
...men det ville en moralsk skandale at aflyse PHEIC..hvor sygdommen stadig raser i Afrika, som ikke har vacciner, og Sydamerika hvor smitten stadig er opadgående...og ikke alle der har købt fra PAHO læste jeg...Mexico har ikke feks...så den kommer tilbage til US...
-
Just one shot of the Mpox vaccine reduces the risk of infection by 86% compared to those who are unvaccinated, according to a new study published recently in Nature Medicine.
https://healthpolicy-watch.news/mpox-vaccine-reduces-infection-risk-by-86-first-real-world-study-in-peer-reviwed-journal-finds/ -
første peer reviwed study...
-
*reviewed
-
Godt nok volatil her
på det sidste... -
Det hele drejer sig om, at BAVA skal levere varen! Så skal kursen nok komme med.
-
Den havde også fået lov til at stige ret meget de seneste dage
-
Der er absolut ingen interesse for det selskab. Vi sidder bare alle med åben mund og kigger på hvordan aktien sejler rundt. Ledelsen siger igen ting, når der kommer ting i pressen der påvirker aktien. Hvis du er leder af et selskab på fondsbørsen, nytter det ikke noget, at du ikke ved hvordan kommunikere med aktionærerne. Jeg er så træt.
-
@Susinvest - der er vel faktisk stilleperiode op til regnskab 2. Marts ?
-
Ledelsen kan tale så meget de vil og nogen er dygtige til at tale kursen op, men i sidste ende er det tallene/data der taler.. og lige nu er der betydelig usikkerhed.. RSV, Covid vacciner.. hvor længe holder MPox “hypen” og hvad er den værd.. osv.. husk at Bav har en mkt værdi på næsten 17 mia allerede idag. Jeg synes ikke det, hverken er urimeligt eller underligt at kursen ligger hvor den gør. Til gengæld synes jeg, at alle dem der købte ind da den lå i omkring kurs 400 måske var lidt hurtige,
-
Verdenssundhedsorganisationen WHO har tirsdag indkaldt til hastemøde, efter der er sket et udbrud af Marburgvirus i Ækvatorialguinea. Bavarian har arbejdet med dette - kender ikkevresultatet… viser igen igen at Bavarian har meget interessant pipeline
-
-
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
The search for a universal filovirus vaccine that provides protection against multiple filovirus species has been prompted by sporadic but highly lethal outbreaks of Ebolavirus and Marburgvirus infections. A good prophylactic vaccine should be able to provide protection to all known filovirus species and as an upside potentially protect from newly emerging virus strains. We investigated the immunogenicity and protection elicited by multivalent vaccines expressing glycoproteins (GP) from Ebola virus (EBOV), Sudan virus (SUDV), Taï Forest virus (TAFV) and Marburg virus (MARV). Immune responses against filovirus GP have been associated with protection from disease. The GP antigens were expressed by adenovirus serotypes 26 and 35 (Ad26 and Ad35) and modified Vaccinia virus Ankara (MVA) vectors, all selected for their strong immunogenicity and good safety profile. Using fully lethal NHP intramuscular challenge models, we assessed different vaccination regimens for immunogenicity and protection from filovirus disease. Heterologous multivalent Ad26-Ad35 prime-boost vaccination regimens could give full protection against MARV (range 75%-100% protection) and EBOV (range 50% to 100%) challenge, and partial protection (75%) against SUDV challenge. Heterologous multivalent Ad26-MVA prime-boost immunization gave full protection against EBOV challenge in a small cohort study. The use of such multivalent vaccines did not show overt immune interference in comparison with monovalent vaccines. Multivalent vaccines induced GP-specific antibody responses and cellular IFNγ responses to each GP expressed by the vaccine, and cross-reactivity to TAFV GP was detected in a trivalent vaccine expressing GP from EBOV, SUDV and MARV. In the EBOV challenge studies, higher humoral EBOV GP-specific immune responses (p = 0.0004) were associated with survival from EBOV challenge and less so for cellular immune responses (p = 0.0320). These results demonstrate that it is feasible to generate a multivalent filovirus vaccine that can protect against lethal infection by multiple members of the filovirus family.
(journals.plos.org)
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind